Call Us : 1.224.938.9523

2023 Program

Friday, March 17, 2023 (10:00 am – 3:40 pm US Eastern Time)
Saturday, March 18, 2023 (10:00 am – 12:40 pm US Eastern Time)

Sunday, April 2, 2023 (1:00 pm – 4:00 pm US Eastern Time)


MCI Symposium Program (Day 1)

Friday, MARCH 17, 2023

All times in US Eastern Time.

10:00 am
12:00 pm
Introductory Notes on the 21st Annual MCI Symposium
SESSION 1: Highlights from Observational Studies of Brain Aging (including, cognition, imaging, blood based biomarkers and longitudinal predictors of decline)
Session Overview
Fluid and Imaging Biomarker Changes in the Swedish BioFINDER 2 Study
Fluid and Imaging Biomarker Changes in the Mayo Clinic Study of Aging
Fluid and Imaging Biomarker Changes in the MYHAT Study (University of Pittsburgh, USA
The Correlation of plasma and Imaging Biomarkers with Clinical Performance in the AIBL and ADNeT Studies
Fluid and Imaging Biomarker Changes in the DIAN Study, Washington Univ. St Louis, USA
Fluid and Imaging Biomarkers for Diagnosis and Predicting Progression
SESSION 2: Trials of Monoclonal Antibodies Directed Against Beta-Amyloid Protein
Session Overview
Clinical and Fluid and Imaging Biomarker Changes from the API ADAD Colombia Trial of Crenezumab
Biomarker changes associated with Clinical Treatment Effects in the Trail Blazer Trials with Donanemab
Biomarker changes associated with clinical treatment effects of Ganterenumab in the DIAN-TU-001 trial
The Clarity AD Trial with Lecanemab and the Potential of Plasma Biomarkers for Tracking Treatment Response
Ranjan Duara, MD, MRCP, FAAN, Mt Sinai Medical Center/Wien Center for Alzheimer's Disease and Memory Disorders
Chairs: Mary Ganguli, MD, MPH, University of Pittsburgh and Ronald Petersen, MD, PhD, Mayo Clinic, Rochester
Oskar Hansson, MD, PhD, Lund University
Alicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester
Thomas Karikari, PhD, University of Pittsburgh
Azadeh Feizpour, PhD, Florey Institute
Brian Gordon, PhD, Washington University in St Louis
Victor Villemagne, MD, University of Pittsburgh
Chair: Eric McDade, DO, Washington University in St Louis and Stephen Salloway, MD, MS, Butler Hospital
Pierre Tariot, MD, Banner Alzheimer's Institute
Adam Fleisher, MD, MAS, Eli Lilly & Co., Inc.
Eric McDade, DO, Washington University in St Louis
Christopher Van Dyck, MD, Yale University

MCI Workshop Program (Day 2)

SATURday, MARCH 18, 2023

All times in US Eastern Time.

10:00 ET
10:05 ET
10:05 am
12:10 pm
Welcome Notes
CSF and Blood Biomarkers for Lewy Body Disease (LBD)
Workshop Overview
Biology and Clinical Features of LBD and Distinction from AD and Other Neurodegenerative Diseases
CSF Biomarker Findings in Lewy Body Dementia versus Alzheimer’s Disease
Differential levels of Plasma Biomarkers of Neurodegeneration in Lewy Body Dementia, Alzheimer’s Disease, Frontotemporal Dementia and Progressive Supranuclear Palsy
KEYNOTE: a-Synuclein RT-QuIC and other Fluid Biomarkers for Assessment across the PD-DLB Spectrum
Ranjan Duara, MD, MRCP, FAAN
Chairs: James Galvin, MD, University of Miami and
Bhavana Patel, DO, MS, University of Florida
James Galvin, MD, University of Miami
Lucilla Parnetti, MD, PhD, University of Perugia
Leonidas Chouliaras, MBBS, PhD, Cambridge University
Douglas Galasko, MD, University of California, San Diego


Ranjan Duara, MD, MRCP, FAAN

Dr. Ranjan Duara, MD, MRCP, FAAN, is the Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center and holds the Denis C. Cole Family Chair in Alzheimer’s Disease Research. In addition, Dr. Duara serves the Associate Director and leader of the Clinical Core of the 1Florida Alzheimer’s Disease Research Center, a research collaboration between four university medical centers and Mount Sinai Medical Center in Florida. Dr. Duara is a Courtesy Professor of Neurology at the University of Florida College of Medicine, Gainesville, Florida, and the Herbert Wertheim College of Medicine, Florida International University, Miami, Florida. He serves as the Principal Investigator of the State of Florida Dementia Brain Bank Program.

Dr. Duara is a clinical neurologist with a special interest in the use of brain imaging for the diagnosis and treatment of Alzheimer’s disease and other causes of Adult Cognitive Disorders. Through his research in this area, he has helped to enhance what is known about the biology of Alzheimer’s disease.

He completed his undergraduate medical education at Christian Medical College, Vellore, South India, completed two years of neurology residency with Dr. Noshir Wadia at Grant Medical College in Bombay, India, followed by residencies in internal medicine and neurology in the United Kingdom, and in neurology at Thomas Jefferson University Hospital in Philadelphia. He then completed a four-year fellowship in neuroscience and neuroimaging of aging, with Dr Stanley Rapaport at the National Institute on Aging (National Institutes of Health, Bethesda, MD).

Dr. Duara’s research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology, and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to more than 250 articles in peer-reviewed scientific journals and has been an investigator in observational studies on aging, as well as clinical trials of novel agents for the treatment of Alzheimer’s Disease. Dr. Duara is also the chair and organizer of the Mild Cognitive Impairment Symposium, which is held annually in Miami Beach.


Alicia Algeciras-Schimnich, PhD

Alicia Algeciras-Schimnich, PhD, is Chair of the Clinical Biochemistry and Immunology Division within the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota.

She holds the academic rank of Associate Professor of Laboratory Medicine and Pathology. Her areas of expertise are tumor markers, endocrine malignancies, maternal serum screening for trisomies and neural tube defects. She is a diplomate of the American Board of Clinical Chemistry and a fellow of the National Academy of Clinical Biochemistry.

Leonidas Chouliaras, MD, PhD

Dr. Leonidas Chouliaras is a National Institute for Health Research (NIHR) Clinical lecturer in Old Age Psychiatry at the University of Cambridge and an honorary specialty registrar at the Cambridgeshire and Peterborough NHS Foundation Trust. He is also an early career researcher representative at the NIHR National Dementias Clinical Research Network and at the Alzheimer’s Research UK (ARUK) East Network Centre.

After medical training at Aristotle University of Thessaloniki, he completed his PhD at the University of Maastricht in 2012 investigating the involvement of epigenetic mechanisms in ageing and Alzheimer’s disease. He then worked as an NIHR Academic Clinical Fellow in Oxford during hid early years of psychiatry training.

Dr. Chouliaras’s research interests include the role of epigenetic mechanisms in neurodegeneration, and particularly in Dementia with Lewy Bodies, Alzheimer’s disease and Mild Cognitive Impairment. He believes that exploring disease driven changes in the epigenetic landscape has the potential to improve our understanding of the pathophysiology of neurodegenerative disorders and aid in the identification of novel pathways as therapeutic targets. Furthermore, work on peripheral epigenetic profiling in combination with multimodal neuroimaging techniques can aid in the development of early risk markers of disease before the onset of any symptoms.

Azadeh Feizpour, PhD

Dr. Azadeh Feizpour completed her PhD in neuroscience at Monash University, Australia, in 2018. Following completion of her doctoral studies, she transitioned to the med-tech industry where she gained more than 3 years of experience in translational research. During this period, she was appointed to the position of Chief Scientist developing digital diagnostics and therapeutics for neurodevelopmental disorders.

Dr Feizpour joined The Florey Institute of Neuroscience and Mental Health as a Senior Research Fellow in 2022 to collaborate with clinicians and researchers on the AIBL and ADNeT studies and contributes to research on emerging Alzheimer’s Disease diagnostics and their translation into clinical practice.

Adam Fleisher, MD, MAS

Dr. Adam Fleisher is a geriatric neurologist and Associate Vice President of Neuroscience Research at Eli Lilly and company. Prior positions at Eli Lilly included Chief Medical Officer at Avid Radiopharmaceuticals and Director of Global Medical Affairs, Alzheimer’s team. From 2008-2014 he was the Director of Imaging at the Banner Alzheimer’s Institute, a site investigator for dementia clinical trials, and cared for patients in the Stead Family memory clinic. He previously held an academic appointment as Associate Professor, Department of Neurosciences, at the University of California, San Diego (UCSD), where he served as the Medical Director of the Alzheimer’s Disease Cooperative Study from 2003-2013.

He received his medical degree from the University of Rochester School of Medicine, New York, and completed general neurology residency training at Johns Hopkins Hospital in Baltimore, Maryland. He completed a clinical and research dementia fellowship at UCSD Diego under Dr. Leon Thal, as well as a Master’s degree of advanced studies in clinical research administration. Adam is well published in the field of Alzheimer’s and other neurodegenerative disorders with a focus on MRI and PET imaging, as well as clinical trials in Alzheimer’s disease.

Douglas Galasko, MD

Douglas Galasko, MD, is a board-certified neurologist with broad expertise in assessing people with changes in memory and cognition, including Alzheimer’s disease, frontotemporal degeneration, dementia with Lewy bodies and cognitive problems associated with Parkinson’s disease.

He is a specialist with Brain Health and Memory Disorders program which offers comprehensive diagnostic testing, with access to brain imaging and comprehensive laboratory testing as needed, medical management and community resources. Patients are also offered access to research opportunities, including potential new treatments.

Dr. Galasko is associate director of the UC San Diego Shiley-Marcos Alzheimer’s Disease Research Center, and has conducted research on Alzheimer’s and related disorders for over 25 years. He has published over 400 research articles on Alzheimer’s disease and related disorders, and has received research funding from the NIH, Michael J. Fox Foundation and Alzheimer’s Drug Discovery Foundation, as well as funding as a clinical trials site.

Dr. Galasko is a member of the American Academy of Neurology and the American Neurological Association.

James Galvin, MD

Dr. James E. Galvin is the Founding Director of the Comprehensive Center for Brain Health and Professor of Neurology and Professor of Psychiatry and Behavioral Sciences at the University of Miami School of Medicine. He is a board-certified Neurologist and Chief of Cognitive Neurology fDivision. Previously, Dr. Galvin served on the Faculty at Hahnemann University, Washington University in St Louis, New York University, and Florida Atlantic University. He is Director and Principal Investigator of the Lewy Body Dementia Association Research Center of Excellence, one of 25 Centers in the United States. 

He has been continuously funded by the National Institutes of Health for more than 20 years and has been awarded nearly 100 million dollars in Federal and State grants. He has published more than 275 peer-reviewed papers in top-tier scientific journals. Dr. Galvin’s research focus is on the develop of novel and innovative approaches to study brain health and the risk of cognitive impairment, holding 13 copyrights for instruments used across the world including the AD8, Quick Dementia Rating System (QDRS), and Lewy Body Composite Risk Score (LBCRS). He leads a multidisciplinary team of physicians, scientists, nurses, social workers, and physical therapists to investigate clinical, cognitive, functional, and behavioral features of healthy brain aging and neurodegenerative disease and their relationship to novel biomarkers of brain pathology including structural, functional and diffusion MRI, amyloid and tau PET scans, blood biomarkers of Alzheimer’s and Parkinson’s disease, electrophysiology, and computer-based behavioral testing. Of particular interest to Dr Galvin and his team is the impact of sex, race, ethnicity, socioeconomic status, and geographic locale on brain health and the risk of future cognitive and functional impairment.

His research has been funded by the National Institutes of Health, Centers for Disease Control, Alzheimer’s Association, American Federation for Aging Research, Michael J Fox Foundation, Association for Frontotemporal Degeneration, Lewy Body Dementia Association, the Departments of Health of Florida, New York and Missouri, and numerous private and family foundations.

Mary Ganguli, MD, MPH

Dr. Mary Ganguli is a geriatric psychiatrist and psychiatric/neuroepidemiologist at the University of Pittsburgh, where she teaches residents, fellows, and graduate students. She provides geriatric psychiatry outpatient services at the University of Pittsburgh Medical Center.

Dr. Ganguli has been conducting population-based studies of cognitive impairment and dementia since 1987. She served on the Neurocognitive Disorders Work Group of DSM-5 and is a member of the AAN Practice Parameter Work Group on MCI. She previously served on the National Advisory Council on Aging.

Dr. Ganguli is Associate Editor of the Journal of the American Geriatrics Society and of International Psychogeriatrics.

Brian Gordon, PhD

Brian A. Gordon, PhD, is an assistant professor of radiology and a principal investigator in the Neuroimaging Labs Research Center, based in Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis, as well as an assistant professor of psychological & brain sciences and biomedical engineering. He is also a faculty member in the Neuroscience PhD program and the interdisciplinary Data Science PhD program.

Trained as a cognitive neuroscientist, Gordon’s research focuses on utilizing advanced neuroimaging techniques such as PET and MRI to understand the complex biology of healthy aging and neurodegenerative disorders. He takes a systems level approach and is interested in how a myriad of factors including genetics, environmental exposures and social influences can act to promote or hinder successful aging.

Gordon completed his doctorate at the University of Illinois, where he utilized MRI, optical imaging and electrophysiological measures (EEG/ERPs) to study aging. After completing a fellowship at Washington University, he transitioned to faculty and obtained an NIH K01 award, which supports early career researchers. He currently leads a project to study tau pathology in autosomal dominant Alzheimer pathology (U19AG032438), is a site-PI on a collaborative study to understand tau pathology (R01AG075336), and is a member of the Knight ADRC imaging core, which supports multiple major grants studying sporadic Alzheimer’s disease. He has also received funding from the American Society for Neuroradiology, the Alzheimer’s Association, the Michael J. Fox Foundation and the Donor Cures Foundation.

Oskar Hansson, MD, PhD

Dr. Oskar Hansson gained his PhD in neurobiology in 2001 and his M.D. in 2005. He became senior consultant in neurology in 2012 at Skåne University Hospital, Sweden, and full professor of neurology in 2017 at Lund University, Sweden. Oskar Hansson has performed internationally recognized clinical and translational research focusing on the earliest phases of Alzheimer’s and Parkinson’s diseases. His landmark study on cerebrospinal fluid biomarkers for Alzheimer’s disease from 2006 (Hansson et al, The Lancet Neurology, 2006) has been instrumental for the implementation of these biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally. His work on biomarkers has led to over 350 original peer-reviewed publications.

Ten years ago, he started the prospective and longitudinal Swedish BioFINDER study (, where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders.

Recently, the BioFINDER team has shown that Tau PET imaging can with high accuracy distinguish Alzheimer’s from all other neurodegenerative diseases (JAMA, 2018) and to detect different subtypes of Alzheimer’s (Nature Medicine 2021), and the team has developed and validated blood-based biomarkers for early detection of Alzheimer’s disease (Nature Medicine, 2020; JAMA, 2020, Nature Aging 2021, Nature Medicine 2021).

Besides being responsible for the outpatient ward of the Memory Clinic at Skåne University Hospital, he is also in leading positions of several research networks and he is co-director of the strategic research area of neuroscience at Lund University.

Thomas Karikari, PhD

Thomas K. Karikari, PhD, is Assistant Professor at University of Pittsburgh and scientist at the Clinical Neurochemistry Laboratory at the University of Gothenburg in Sweden. His main research interest is to further understand molecular and biochemical basis of pathological changes in the Alzheimer brain and apply this knowledge to develop new biofluid-based diagnostic tools for clinical use. To this end, he uses advanced and highly sensitive clinical chemistry techniques that allow quantification of tiny differences in biomarker concentrations in blood and cerebrospinal fluid. Thomas has received major scientific awards for his discovery and development of blood p-tau biomarkers, including from the Swedish Alzheimer Foundation and the Nordic Federation for Clinical Chemistry.

He completed his undergraduate studies in biochemistry at the Kwame Nkrumah University of Science and Technology in Kumasi, Ghana, followed by a Master’s degree in pharmaceutical biotechnology in Leicester, England. Thomas received his PhD in 2018 from Warwick university in Coventry, England, where he developed and applied biochemical, molecular and cell biology approaches to investigate functional and structural consequences of genetic mutations in the MAPT gene associated with different tauopathies.

At the end of his PhD, Thomas was a visiting scholar at Harvard Medical School where he investigated kinetic cytotoxicity of aggregated tau. He then moved to Gothenburg, Sweden, as a postdoctoral fellow in clinical chemistry under the mentorship of Professors Kaj Blennow and Henrik Zetterberg.

Eric McDade, DO

Dr. Eric McDade focuses on identifying critical interactions between vascular disease and neurodegenerative disease. His current research combines neuroimaging, clinical evaluation, and basic science with an end goal of identifying better measures and targets for interventions and prevention relating to cognitive aging. He serves as principal investigator for the DIAN observational trial, the DIAN treatment trial, and the Knight Family DIAN-TU primary prevention trial.

Dr. McDade earned his bachelor’s degree from Canisius College and his medical degree from Chicago College of Osteopathic Medicine. He completed his residency at the University of Maryland School of Medicine, where he also served as a chief resident, and his fellowship training in cognitive and behavioral neurology at the Mayo Clinic. He was an assistant professor of neurology at the University of Pittsburgh from 2010-15 and joined the Washington University faculty as an associate professor in 2015.

Lucilla Parnetti, MD, PhD

Dr. Lucilla Parnetti is Professor in Neurology at University of Perugia and Head of Center for Memory Disturbances whiten the Neurology Clinic at Perugia University Hospital. Her main expertise in on the field of cerebrospinal fluid biomarkers for early diagnosis of neurodegenerative diseases, with special interest on Alzheimer’s disease and Parkinson’s disease.

She authored more than 300 papers and her research was funded by the European Commission, Italian Ministry of University and Research, Italian Ministry of Health, Michael J. Fox Foundation for Parkinson research.

She is Vice-President of the Society for CSF analysis and Clinical Neurochemistry and member of Editorial Board of Movement Disorders and Journal of Alzheimer Disease.

Bhavana Patel, DO, MS

Dr. Bhavana Patel, DO, MS is currently an assistant professor in the Division of Movement disorders and Behavioral Neurology at the University of Florida. She joined the UF Department of Neurology and the Fixel Institute in 2019.

Dr. Patel graduated from Butler University in 2008 with a double major in chemistry and Spanish, followed by a Master’s degree in Biology at Purdue University in Indianapolis. She completed medical school at the West Virginia School of Osteopathic medicine in 2013, followed by a preliminary internal medicine year and neurology residency at University of Kansas in 2017. During her residency she received awards for her residency research projects and was recognized by the medical student body for her excellence in teaching. In her final year of training she served as Chief Resident.

Upon completion of her neurology training she pursued a two year fellowship in Movement Disorders and additional training in cognitive disorders and dementias at UF from 2017-2019. She has a personal connection to Dementia with Lewy Bodies and during her training she completed additional clinical and research training in Lewy Body disease under the mentorship of Dr. Melissa Armstrong. In 2018 she was the inaugural recipient of the Clinical Research Training Scholarship in Dementia with Lewy Bodies from the American Brain Foundation and the Mary E. Groff Charitable trust, in collaboration with the American Academy of Neurology.

Dr. Patel’s research interests include improving the delivery of specialized healthcare in Lewy body dementia, applications of technology to improve health outcomes, and neurostimulation for movement and cognitive disorders.

Currently her NIH funded research focuses on developing a LBD centric telemedicine program with access to a multidisciplinary team of exerts in LBD and using smartwatch technology to objectively measure life space mobility.

She has presented her research at multiple international conferences including an International Lewy Body Dementia Conference, International Congress of Parkinson’s Disease and Movement Disorder Society, Academy of Neurology, and World Parkinson Congress.

Ronald Petersen, MD, PhD

Dr. Ronald Petersen is a national leader in the field of Alzheimer’s research. He is the director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study on Aging. He has authored over 550 peer-reviewed articles and edited five books on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen received his Ph.D. in Experimental Psychology from the University of Minnesota and graduated from Mayo Medical School in 1980. He joined the staff of the Mayo Clinic in 1986. He became the Cora Kanow Professor of Alzheimer’s Disease Research in 2000, and was named the Mayo Clinic Distinguished Investigator in 2011.

Dr. Ronald Petersen is one of the recipients of the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s, and Related Disorders of the American Academy of Neurology. He also received the inaugural Ronald and Nancy Reagan Research Institute Award in 2004 from the Alzheimer’s Association and the inaugural Leon Thal Prize of the Lou Ruvo Brain Institute in 2007. In 2012, he received the Khachaturian award of the Alzheimer’s Association and the Henry Wisniewski Lifetime Achievement Award in 2013.

In 2011, he was appointed by the Secretary of Health and Human Services to serve as the chair of the Advisory Committee on Research, Care, and Services for the National Alzheimer’s Project Act and was appointed to the World Dementia Council in 2014 by UK Prime Minister David Cameron.

Stephen Salloway, MD, MS

Stephen Salloway, MD, MS, is the founding Director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island. He is the Martin M. Zucker Professor of Psychiatry and Human Behavior and Professor of Neurology at the Warren Alpert Medical School of Brown University. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University.

His research focuses on biomarker and drug development for prevention and early treatment of Alzheimer’s disease (AD). During his time at Brown, the Butler Hospital Memory and Aging Program (MAP) has become an internationally recognized center for clinical research in Alzheimer’s disease. The MAP has helped pioneer the use of PET ligands for amyloid and tau to study the evolution of AD pathophysiology in autosomal dominant and sporadic AD. The program has had a lead role in testing targeted treatments, such as BACE inhibitors and monoclonal antibodies, alone and in combination, to lower amyloid plaques and neurofibrillary tangles, as well as novel approaches, such as deep brain stimulation, to slow the progression of AD. The MAP is developing new strategies using genetic testing and brain imaging to recruit cognitively normal elderly at increased risk for AD for prevention studies.

Dr. Salloway has published more than 370 scientific articles and abstracts and has edited 3 books. These include lead authorship on pivotal trials in the New England Journal of Medicine, the Lancet, Nature, and JAMA Neurology. Dr. Salloway is a past president of the American Neuropsychiatric Association, a fellow of the American Academy of Neurology, and a member of the American Neurological Association. He serves on the Steering Committees for landmark NIH studies such as the Alzheimer’s Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer’s Network, and the Alzheimer’s Disease Clinical Trial Consortium. He is a scientific reviewer for the National Institutes of Health and for more than 30 journals, universities, and research foundations. Dr. Salloway lectures widely on prevention and early intervention for Alzheimer’s disease.

Pierre Tariot, MD

Dr. Pierre N. Tariot has served as Institute Director for Banner Alzheimer’s Institute since its inception in 2006 in addition to his roles as a clinician, researcher and leader. He serves as co-director of the international Alzheimer’s Prevention Initiative, which is credited with helping launch a new era in Alzheimer’s prevention research. Dr. Tariot also leads Banner Dementia Care Partners, a program designed to demonstrate the clinical and cost-effectiveness of standardized care for persons with dementia in a large health care system, and is a Research Professor of Psychiatry at the University of Arizona College of Medicine.

Dr. Tariot’s work has focused on care and study of people with and at risk for Alzheimer’s disease, with special emphasis on design and implementation of clinical trials for prevention and treatment, development of biomarkers, measurement and treatment of neuropsychiatric features of dementia and demonstration of effective dementia care. His experience includes conceiving, funding and implementing single-center and multicenter trials, and serving as Principal Investigator on over 50 clinical trials related to Alzheimer’s disease and related dementias. He has published over 400 papers on these topics, including those regarding studies that have led to FDA approval of new medications.

Dr. Tariot is Board Certified in Internal Medicine and Psychiatry with added qualifications in geriatrics. He was a Fellow at the National Institute of Mental Health (NIMH) Intramural Research Program and then served as a faculty member at the University of Rochester Medical Center.

His research affiliations include the National Institute on Aging (NIA), the NIMH, and the Alzheimer’s Association, and he is a Fellow of the American College of Neuropsychopharmacology. His work has been recognized throughout his career earning him many awards, including the American Geriatrics Society New Investigator Award for Neuroscience, Arizona Geriatrics Society Geriatrician of the Year, National Institute of Mental Health Geriatric Mental Health Academic Award and the UCLA Turken Research Award.

Christopher Van Dyck, MD

Christopher Van Dyck, MD, is Professor of Psychiatry, Neurology, and Neuroscience; Director of the Alzheimer’s Disease Research Unit; Director, Yale Alzheimer’s Disease Research Center; Director, Division of Aging and Geriatric Psychiatry.

His research focuses on neuroimaging and therapeutic studies of Alzheimer’s disease (AD) and brain aging. His current imaging research utilizes positron emission tomography (PET) to study the beta-amyloid (Aβ) and tau proteins, as well as the synaptic targets SV2A and mGluR5. He and his team are examining the full spectrum of AD, including AD-dementia, the prodromal condition of amnestic Mild Cognitive Impairment (aMCI), and preclinical AD—in individuals at high familial and genetic risk.

He also has extensive experience in the conduct and leadership of therapeutic trials in AD. Since 1991 he has led or participated in approximately 90 clinical trials for AD, including the prodromal or preclinical stages. He currently serves on the Steering and Executive Committees and Co-Chairs the Protocol Evaluation Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). His research accomplishments have been recognized by receipt of the 1996 Junior Investigator Award of the American Association of Geriatric Psychiatry, the 2005 Compassion and Cure Award of the Alzheimer’s Association, and the 2017 Leader in Advancing Research Award of the Alzheimer’s Association.

, is Professor of Psychiatry, Neurology, and Neuroscience; Director of the Alzheimer’s Disease Research Unit; Director, Yale Alzheimer’s Disease Research Center; Director, Division of Aging and Geriatric Psychiatry.

His research focuses on neuroimaging and therapeutic studies of Alzheimer’s disease (AD) and brain aging. His current imaging research utilizes positron emission tomography (PET) to study the beta-amyloid (Aβ) and tau proteins, as well as the synaptic targets SV2A and mGluR5. He and his team are examining the full spectrum of AD, including AD-dementia, the prodromal condition of amnestic Mild Cognitive Impairment (aMCI), and preclinical AD—in individuals at high familial and genetic risk.

He also has extensive experience in the conduct and leadership of therapeutic trials in AD. Since 1991 he has led or participated in approximately 90 clinical trials for AD, including the prodromal or preclinical stages. He currently serves on the Steering and Executive Committees and Co-Chairs the Protocol Evaluation Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). His research accomplishments have been recognized by receipt of the 1996 Junior Investigator Award of the American Association of Geriatric Psychiatry, the 2005 Compassion and Cure Award of the Alzheimer’s Association, and the 2017 Leader in Advancing Research Award of the Alzheimer’s Association.

Victor Villemagne, MD

Dr. Victor Villemagne graduated Cum Laude from the National University of Buenos Aires in 1983. He was awarded a Post-Doctoral Fellowship in Nuclear Medicine by the National Atomic Energy Commission in 1984, and continued his post-graduate studies at the Division of Nuclear Medicine at Johns Hopkins Medical Institutions. He subsequently furthered his molecular neuroimaging training at the National Institute on Drug Abuse, NIH, and the University of Pittsburgh. He now holds the appointment of Senior Research Fellow in Neuroscience at the PET Centre, Austin Hospital. Since 2003, he has performed several preclinical studies of new tracers for A? and tau with in vitro techniques and animal models and human PET and SPECT studies – including blood metabolite analysis and kinetic modeling for quantification of binding parameters- at Austin Health. A/Prof Villemagne have been principal or co-investigator in several national and international grants.

Prof Villemagne has authored or co-authored ten book chapters, several requested reviews on dementia imaging, and more than 200 original research publications, with senior or first author papers on PET research in leading international peer-reviewed journals, particularly in the field of neuroreceptor and amyloid imaging studies. He has been invited to chair and present at national and international meetings in the area of biomarkers for Alzheimer’s disease and neurodegeneration. Among other honours, he has received the Foerderer Fund for Excellence Award from The Children’s Hospital of Philadelphia in 2002, the JAAME Fellowship from Japan in 2007 and the ANSTO Nuclear Medicine Award in 2010. More recently, he received the de Leon Prize in Neuroimaging – Senior Scientist by the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (2013), and the Christopher Clark Award for the Continuing Advancement in the Field of Human Amyloid Imaging, Miami (2014).

Public Educational Forum Program

Sunday, April 2, 2023

1:00 PM US Eastern Time.